85. Idiopathic interstitial pneumonia Clinical trials / Disease details
Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05241275 (ClinicalTrials.gov) | March 1, 2022 | 3/2/2022 | Xenon MRI and Progressive ILD | XENON ILD: 129Xe MRI to Evaluate aNtifibrotic respOnse and progressioN in ILD | Idiopathic Pulmonary Fibrosis;Progressive Pulmonary Fibrosis | Drug: Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment | Duke University | Boehringer Ingelheim | Not yet recruiting | 18 Years | N/A | All | 75 | Phase 2 | NULL |
2 | NCT04071769 (ClinicalTrials.gov) | August 3, 2020 | 9/8/2019 | Genentech Xenon MRI Idiopathic Pulmonary Fibrosis | Using Xenon MRI to Evaluate the Efficacy of Therapies for Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment | Duke University | NULL | Recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |
3 | NCT02478268 (ClinicalTrials.gov) | May 2015 | 16/6/2015 | Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis | Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Hyperpolarized 129-Xenon gas;Device: MRI | Bastiaan Driehuys | University of Wisconsin, Madison;National Heart, Lung, and Blood Institute (NHLBI) | Completed | 18 Years | N/A | All | 64 | Phase 1 | United States |